O	0	7	Quality
O	8	10	of
O	11	15	life
O	16	21	under
B-control	22	30	extended
I-control	31	41	continuous
O	42	48	versus
B-intervention	49	61	intermittent
I-intervention	62	70	adjuvant
I-intervention	71	80	letrozole
O	81	83	in
O	84	89	lymph
O	90	94	node
O	94	95	-
O	95	103	positive
O	103	104	,
O	105	110	early
O	111	117	breast
O	118	124	cancer
O	125	133	patients
O	133	134	:
O	135	138	the
O	139	143	SOLE
O	144	154	randomised
O	155	160	phase
O	161	162	3
O	163	168	trial
O	168	169	.

O	170	172	In
O	173	176	the
O	177	182	phase
O	183	186	III
O	187	191	SOLE
O	192	197	trial
O	197	198	,
O	199	202	the
O	203	211	extended
O	212	215	use
O	216	218	of
O	219	231	intermittent
O	232	238	versus
O	239	249	continuous
O	250	259	letrozole
O	260	263	for
O	264	265	5
O	266	271	years
O	272	275	did
O	276	279	not
O	280	287	improve
O	288	295	disease
O	295	296	-
O	296	300	free
O	301	309	survival
O	310	312	in
O	313	327	postmenopausal
O	328	333	women
O	334	338	with
O	339	346	hormone
O	347	355	receptor
O	355	356	-
O	356	364	positive
O	365	371	breast
O	372	378	cancer
O	378	379	.

O	380	392	Intermittent
O	393	400	therapy
O	401	405	with
O	406	407	3
O	407	408	-
O	408	413	month
O	414	420	breaks
O	421	424	may
O	425	427	be
O	428	438	beneficial
O	439	442	for
O	443	451	patients
O	451	452	'
O	453	460	quality
O	461	463	of
O	464	468	life
O	469	470	(
O	470	473	QoL
O	473	474	)
O	474	475	.

O	476	478	In
O	479	482	the
O	483	487	SOLE
O	488	491	QoL
O	492	495	sub
O	495	496	-
O	496	501	study
O	501	502	,
B-total-participants	503	506	956
O	507	515	patients
O	516	525	completed
O	526	529	the
O	530	536	Breast
O	537	543	Cancer
O	544	554	Prevention
O	555	560	Trial
O	561	562	(
O	562	566	BCPT
O	566	567	)
O	568	575	symptom
O	576	579	and
O	580	587	further
O	588	591	QoL
O	592	598	scales
O	599	601	up
O	602	604	to
O	605	607	24
O	608	614	months
O	615	620	after
O	621	634	randomisation
O	634	635	.

O	636	647	Differences
O	648	650	in
O	651	657	change
O	658	660	of
O	661	664	QoL
O	665	669	from
O	670	678	baseline
O	679	686	between
O	687	690	the
O	691	694	two
O	695	709	administration
O	710	719	schedules
O	720	724	were
O	725	731	tested
O	732	734	at
O	735	737	12
O	738	741	and
O	742	744	24
O	745	751	months
O	752	757	using
O	758	766	repeated
O	767	775	measures
O	776	781	mixed
O	781	782	-
O	782	788	models
O	788	789	.

O	790	793	The
O	794	801	primary
O	802	809	outcome
O	810	813	was
B-outcome-Measure	814	820	change
I-outcome-Measure	821	823	in
I-outcome-Measure	824	827	hot
I-outcome-Measure	828	835	flushes
I-outcome-Measure	836	838	at
I-outcome-Measure	839	841	12
I-outcome-Measure	842	848	months
O	848	849	.

O	850	855	There
O	856	859	was
O	860	862	no
O	863	873	difference
O	874	876	in
B-outcome	877	880	hot
I-outcome	881	888	flushes
I-outcome	889	891	at
I-outcome	892	894	12
I-outcome	895	901	months
O	902	909	between
O	910	913	the
O	914	917	two
O	918	927	schedules
O	927	928	,
O	929	932	but
O	933	941	patients
O	942	951	receiving
O	952	964	intermittent
O	965	974	letrozole
O	975	983	reported
O	984	997	significantly
O	998	1002	more
O	1003	1014	improvement
O	1015	1017	at
O	1018	1020	24
O	1021	1027	months
O	1027	1028	.

O	1029	1033	They
O	1034	1038	also
O	1039	1048	indicated
O	1049	1053	less
O	1054	1063	worsening
O	1064	1066	in
B-outcome	1067	1074	vaginal
I-outcome	1075	1083	problems
O	1083	1084	,
B-outcome	1085	1100	musculoskeletal
I-outcome	1101	1105	pain
O	1105	1106	,
B-outcome	1107	1112	sleep
I-outcome	1113	1124	disturbance
O	1124	1125	,
B-outcome	1126	1134	physical
I-outcome	1135	1139	well
I-outcome	1139	1140	-
I-outcome	1140	1145	being
O	1146	1149	and
B-outcome	1150	1154	mood
O	1155	1157	at
O	1158	1160	12
O	1161	1167	months
O	1167	1168	.

O	1169	1176	Overall
O	1176	1177	,
O	1178	1180	25
O	1180	1181	-
O	1181	1183	30
O	1183	1184	%
O	1185	1187	of
O	1188	1196	patients
O	1197	1205	reported
O	1206	1207	a
B-outcome	1208	1218	clinically
I-outcome	1219	1227	relevant
I-outcome	1228	1237	worsening
I-outcome	1238	1240	in
I-outcome	1241	1244	key
I-outcome	1245	1253	symptoms
I-outcome	1254	1257	and
I-outcome	1258	1264	global
I-outcome	1265	1268	QoL
O	1268	1269	.

O	1270	1274	Less
O	1275	1282	symptom
O	1283	1292	worsening
O	1293	1296	was
O	1297	1305	observed
O	1306	1312	during
O	1313	1316	the
O	1317	1322	first
O	1323	1327	year
O	1328	1330	of
O	1331	1339	extended
O	1340	1349	treatment
O	1350	1354	with
O	1355	1358	the
O	1359	1371	intermittent
O	1372	1386	administration
O	1386	1387	.

O	1388	1391	For
O	1392	1397	women
O	1398	1410	experiencing
O	1411	1413	an
O	1414	1423	increased
O	1424	1431	symptom
O	1432	1438	burden
O	1439	1441	of
O	1442	1450	extended
O	1451	1459	adjuvant
O	1460	1469	endocrine
O	1470	1477	therapy
O	1477	1478	,
O	1479	1481	an
O	1482	1494	intermittent
O	1495	1509	administration
O	1510	1512	is
O	1513	1514	a
O	1515	1519	safe
O	1520	1531	alternative
O	1531	1532	.

O	1533	1541	Clinical
O	1542	1547	trial
O	1548	1559	information
O	1559	1560	:
O	1561	1572	NCT00651456
O	1572	1573	.
